Health Care [ 8/12 ] | Biotechnology [ 28/73 ]
NASDAQ | Common Stock
Lantern Pharma Inc. focuses on the discovery and development of oncology drug.
Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, as well as glioblastoma and other central nervous system (CNS) cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma.
The company also develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and several rare pediatric CNS cancers.
In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment.
The company has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications; a collaboration agreement with TTC Oncology, which focuses on the drug development of TTC-352 to treat patients with metastatic ER+ breast cancer; and a collaboration agreement with Actuate Therapeutics, Inc. that focuses on the development of compounds for use in the treatment of cancer and inflammatory diseases.
The company was incorporated in 2013 and is headquartered in Dallas, Texas.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 7, 25 | -0.42 Increased by +17.65% | -0.43 Increased by +2.33% |
| Mar 17, 25 | -0.54 Decreased by -38.46% | -0.51 Decreased by -5.88% |
| Nov 7, 24 | -0.42 Decreased by -44.83% | -0.56 Increased by +25.00% |
| Aug 8, 24 | -0.46 Decreased by -4.55% | -0.55 Increased by +16.36% |
| May 9, 24 | -0.51 Decreased by -41.67% | -0.43 Decreased by -18.60% |
| Mar 18, 24 | -0.39 Decreased by -25.81% | -0.40 Increased by +2.50% |
| Nov 8, 23 | -0.29 Decreased by -38.10% | -0.45 Increased by +35.56% |
| Aug 9, 23 | -0.44 Decreased by -7.32% | -0.43 Decreased by -2.33% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 100.65 K Increased by +N/A% | -4.54 M Increased by +16.62% | Decreased by -4.51 K% Decreased by N/A% |
| Dec 31, 24 | 0.00 Decreased by -100.00% | -5.88 M Decreased by -40.36% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -4.51 M Decreased by -42.52% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -4.96 M Decreased by -4.49% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -5.44 M Decreased by -57.74% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 261.05 K Increased by +N/A% | -4.19 M Decreased by -23.80% | Decreased by -1.60 K% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -3.16 M Decreased by -32.61% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -4.75 M Decreased by -3.41% | Decreased by N/A% Decreased by N/A% |